Chan Anthony W H, Chan Ronald C K, Wong Grace L H, Wong Vincent W S, Choi Paul C L, Chan Henry L Y, To Ka-Fai
Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China.
Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
J Gastroenterol Hepatol. 2015 Sep;30(9):1391-6. doi: 10.1111/jgh.12938.
Serum albumin and bilirubin are the most significant independent prognostic factors to predict hepatic events in patients with primary biliary cirrhosis (PBC). We aimed to investigate the prognostic significance of a new prognostic score, the albumin-bilirubin (ALBI) score, among PBC patients.
In a retrospective longitudinal cohort of 61 Chinese PBC patients with follow-up period up to 18.3 years, the prognostic performance of the ALBI in prediction of hepatic events was compared with other well-established prognostic scores: Child-Pugh score, model of end-stage liver disease, Mayo risk score, Yale, European, and Newcastle models.
Fifteen patients (24.6%) developed hepatic events during follow-up. The c-index (0.894) and χ(2) by likelihood ratio test (36.34) of the ALBI score were highest in comparison to other models. The ALBI score was the only independent prognostic factor by multivariate analysis and its adjusted hazard ratio of developing hepatic event was 27.8 (P < 0.001). There were three prognostically different groups stratified by the ALBI score: ALBI grade 1 (≤ -2.60), grade 2 (> -2.60 to -1.39), and grade 3 (> -1.39) groups. The 2-, 5-, and 10-year event-free survivals for grade 1, grade 2, and grade 3 groups were 100.0% versus 100.0% versus 57.1%, 100.0% versus 88.5% versus 14.3%, and 100.0% versus 81.7% versus 0.0%, respectively (P < 0.001).
The ALBI score is readily derived from a blood test without using those factors evaluated subjectively or obtained by invasive procedures. It is an independent prognostic factor for PBC patients and provides better/similar prognostic performance compared with other prognostic scores.
血清白蛋白和胆红素是预测原发性胆汁性肝硬化(PBC)患者肝脏事件的最重要的独立预后因素。我们旨在研究一种新的预后评分——白蛋白-胆红素(ALBI)评分在PBC患者中的预后意义。
在一项对61例中国PBC患者进行的回顾性纵向队列研究中,随访期长达18.3年,将ALBI预测肝脏事件的预后性能与其他成熟的预后评分进行比较:Child-Pugh评分、终末期肝病模型、梅奥风险评分、耶鲁模型、欧洲模型和纽卡斯尔模型。
15例患者(24.6%)在随访期间发生肝脏事件。与其他模型相比,ALBI评分的c指数(0.894)和似然比检验的χ²值(36.34)最高。多因素分析显示,ALBI评分是唯一的独立预后因素,其发生肝脏事件的调整后风险比为27.8(P<0.001)。根据ALBI评分可分为三个预后不同的组:ALBI 1级(≤ -2.60)、2级(> -2.60至-1.39)和3级(> -1.39)组。1级、2级和3级组的2年、5年和10年无事件生存率分别为100.0%对100.0%对57.1%、100.0%对88.5%对14.3%、100.0%对81.7%对0.0%(P<0.001)。
ALBI评分可通过血液检测轻松得出,无需使用主观评估的因素或通过侵入性操作获得的因素。它是PBC患者的独立预后因素,与其他预后评分相比,具有更好/相似的预后性能。